MAIA Biotechnology to Present at Two Investor Conferences in April 2024
MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that Chairman and Chief Executive Officer Vlad Vitoc, M.D. will present at two investor conferences during the month of April: the 14th Annual LD Micro Invitational taking place April 8-9, 2024, in New York City; and the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference taking place April 17-18, 2024.
LD Micro:
Presentation: |
04:30PM ET on April 09, 2024* |
Format: |
In-person and virtual |
Location: |
Sofitel New York, New York City |
Conference registration: |
Visit the conference website |
Livestream registration: |
Visit Sequire Events |
1x1 meetings: |
Upon request by registered investors |
Noble Capital Markets:
Presentation: |
11:00AM ET on April 17, 2024* |
Format: |
Virtual |
Conference registration: |
Visit the conference website |
1x1 meetings: |
Upon request by registered investors |
*Please note that the presentation date and time are subject to change. Participants should refer to the final program agendas for up-to-date information.
Lesen Sie auch
MAIA’s lead candidate is THIO, a small molecule telomere-targeting anticancer agent that acts by producing direct telomeric DNA damage and inducing cancer-specific immune responses. THIO’s efficacy in non-small cell lung cancer (NSCLC) is being evaluated in THIO-101, a Phase 2 go-to-market clinical trial nearing completion, which is expected to be the first completed clinical study of a telomere-targeting agent in the field of cancer drug discovery and treatment. MAIA plans to pursue the FDA’s accelerated approval program for THIO.